Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1167 as Adjunctive Therapy in Mild to Moderate Alzheimer's Disease Dementia
NCT06721156Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of MK-1167 in Alzheimer's disease (AD), sponsored by Merck & Co.. Started Dec 2024; status: terminated.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06721156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721156.